<DOC>
	<DOCNO>NCT03085056</DOCNO>
	<brief_summary>The purpose study test safety tolerability treatment combination paclitaxel trametinib . Additionally , study aim find effect combination paclitaxel trametinib shrinkage growth anaplastic thyroid cancer .</brief_summary>
	<brief_title>Trametinib Combination With Paclitaxel Treatment Anaplastic Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Thyroid Carcinoma , Anaplastic</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Pathologically ( histologically cytologically ) proven diagnosis anaplastic thyroid cancer ( diagnosis note consistent anaplastic thyroid cancer acceptable ) . Metastatic disease localregional disease consider resectable cure . Patients must measurable disease per RECIST v1.1 criterion , define least one lesion accurately measure least one dimension ( long diameter record nonnodal lesion short axis nodal lesion ) ≥20 mm conventional technique ≥10 mm spiral CT scan , MRI , caliper clinical exam Age ≥18 year ECOG performance status ≤2 ( Karnofsky ≥60 ) Able swallow retain orallyadministered medication clinically significant gastrointestinal abnormality may alter absorption , malabsorption syndrome major resection stomach bowels No CTCAE v4 grade &gt; 2 neuropathy Patients must normal organ marrow function define : Absolute neutrophil count ( ANC ) ≥1.5x10^9/L Hemoglobin ≥9 g/dL Platelets ≥100x10^9/L Serum bilirubin ≤1.5x institutional upper limit normal ( ULN ) ( Unless Gilbert 's Disease case total bilirubin ≤3x institutional ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5x institutional ULN ( ≤5x institutional ULN liver metastasis ) Serum creatinine ≤1.5 mg/dL OR calculate creatinine clearance ( CockcroftGault formula ) ≥50 mL/min OR 24hour urine creatinine clearance ≥50 mL/min Left ventricular ejection fraction ≥ institutional low limit normal ( LLN ) ECHO MUGA Negative pregnancy test ( serum urine ) within 14 day registration woman childbearing potential . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Men treat enrol protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion trametinib administration Ability understand willingness sign write informed consent document . Patients chemotherapy radiotherapy within 21 day enrollment . Use investigational drug within 28 day ( five halflives , whichever short ; minimum 14 day last dose ) precede first dose trametinib study Symptomatic untreated brain metastasis , leptomeningeal disease , spinal cord compression History interstitial lung disease pneumonitis History current evidence/risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) : History RVO CSR , predispose factor RVO CSR ( e.g. , uncontrolled glaucoma ocular hypertension ) Visible retinal pathology assess ophthalmic exam consider high risk factor RVO CSR evidence new optic disc cupping , evidence new visual field defect , intraocular pressure &gt; 21 mm Hg History evidence cardiovascular risk include follow : LVEF &lt; LLN A QT interval correct heart rate use Bazett 's formula QTcB ≥480 msec History evidence current clinically significant uncontrolled arrhythmia ( exception : patient control atrial fibrillation &gt; 30 day prior enrollment eligible ) History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization History evidence current ≥ Class II congestive heart failure define New York Heart Association ( NYHA ) functional classification system Treatmentrefractory hypertension define blood pressure systolic &gt; 150 mmHg and/or diastolic &gt; 90 mmHg control antihypertensive therapy Known cardiac metastasis Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( exception chronic clear HBV HCV infection , allow ) HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction trametinib . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Any condition may impair ability absorb oral medications/investigational product include : prior surgical procedure affect absorption include , limited major resection stomach small bowel ; active peptic ulcer disease ; malabsorption syndrome Any major surgery within 21 day prior enrollment . Have know immediate delay hypersensitivity reaction idiosyncrasy taxanes drug chemically relate trametinib , excipients dimethyl sulfoxide ( DMSO ) Current use prohibit medication . The following medication nondrug therapy prohibit : Concurrent treatment bisphosphonates permit ; however , treatment must initiate prior first dose study therapy . Prophylactic use bisphosphonates patient without bone disease permit , except treatment osteoporosis Because composition , PK , metabolism many herbal supplement unknown , concurrent use herbal supplement prohibit study ( include , limited , St. John 's wort , kava , ephedra [ huang ] , gingko biloba , dehydroepiandrosterone [ DHEA ] , yohimbe , saw palmetto , ginseng )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Trametinib</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>15-055</keyword>
</DOC>